Pharma Equity Group A/S Cl A (PEG) - Net Assets

Latest as of December 2025: Dkr25.47 Million DKK ≈ $3.99 Million USD

Based on the latest financial reports, Pharma Equity Group A/S Cl A (PEG) has net assets worth Dkr25.47 Million DKK (≈ $3.99 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr38.90 Million ≈ $6.09 Million USD) and total liabilities (Dkr13.43 Million ≈ $2.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Pharma Equity Group A/S Cl A to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Dkr25.47 Million
% of Total Assets	65.48%
Annual Growth Rate	-4.55%
5-Year Change	-40.16%
10-Year Change	-73.68%
Growth Volatility	100.34

Pharma Equity Group A/S Cl A - Net Assets Trend (2008–2025)

This chart illustrates how Pharma Equity Group A/S Cl A's net assets have evolved over time, based on quarterly financial data. Also explore PEG asset base for the complete picture of this company's asset base.

Annual Net Assets for Pharma Equity Group A/S Cl A (2008–2025)

The table below shows the annual net assets of Pharma Equity Group A/S Cl A from 2008 to 2025. For live valuation and market cap data, see market cap of Pharma Equity Group A/S Cl A.

Year	Net Assets	Change
2025-09-30	Dkr25.47 Million ≈ $3.99 Million	-47.88%
2024-09-30	Dkr48.88 Million ≈ $7.65 Million	+92.93%
2023-09-30	Dkr25.33 Million ≈ $3.96 Million	-44.98%
2022-09-30	Dkr46.05 Million ≈ $7.20 Million	+8.17%
2021-09-30	Dkr42.57 Million ≈ $6.66 Million	+24.17%
2020-09-30	Dkr34.28 Million ≈ $5.36 Million	-48.95%
2019-09-30	Dkr67.16 Million ≈ $10.51 Million	-13.43%
2018-09-30	Dkr77.57 Million ≈ $12.14 Million	-8.84%
2017-09-30	Dkr85.09 Million ≈ $13.31 Million	-12.08%
2016-09-30	Dkr96.78 Million ≈ $15.14 Million	-2.77%
2015-09-30	Dkr99.53 Million ≈ $15.57 Million	+1.62%
2014-09-30	Dkr97.95 Million ≈ $15.32 Million	+192.90%
2013-09-30	Dkr-105.44 Million ≈ $-16.50 Million	-389.77%
2012-09-30	Dkr36.39 Million ≈ $5.69 Million	-54.33%
2011-09-30	Dkr79.67 Million ≈ $12.46 Million	+50.13%
2010-09-30	Dkr53.06 Million ≈ $8.30 Million	-0.76%
2009-09-30	Dkr53.47 Million ≈ $8.37 Million	-4.95%
2008-09-30	Dkr56.25 Million ≈ $8.80 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Pharma Equity Group A/S Cl A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 6657900000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (September 2025)

Component	Amount	Percentage
Common Stock	Dkr122.76 Million	481.93%
Other Comprehensive Income	Dkr-97.28 Million	-381.93%
Total Equity	Dkr25.47 Million	100.00%

Pharma Equity Group A/S Cl A Competitors by Market Cap

The table below lists competitors of Pharma Equity Group A/S Cl A ranked by their market capitalization.

Company	Market Cap
Landmarks Bhd KLSE:1643	$15.17 Million
DAVIDsTEA Inc F:DAT	$15.18 Million
Noble Mineral Exploration Inc V:NOB	$15.18 Million
Botala Energy Ltd AU:BTE	$15.18 Million
Envoy Medical Inc. NASDAQ:COCH	$15.17 Million
Guardforce AI Co Ltd NASDAQ:GFAI	$15.16 Million
Tomypak Holdings Bhd KLSE:7285	$15.15 Million
ADTIGER CORP.LTD.DL-0005 F:55U	$15.15 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pharma Equity Group A/S Cl A's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 48,875,000 to 25,472,000, a change of -23,403,000 (-47.9%).
Net loss of 25,382,000 reduced equity.
Other comprehensive income decreased equity by 97,284,000.
Other factors increased equity by 99,263,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Dkr-25.38 Million	-99.65%
Other Comprehensive Income	Dkr-97.28 Million	-381.93%
Other Changes	Dkr99.26 Million	+389.69%
Total Change	Dkr-	-47.88%

Book Value vs Market Value Analysis

This analysis compares Pharma Equity Group A/S Cl A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.81x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 0.00x to 3.81x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2008-09-30	Dkr66.77	Dkr0.08	x
2009-09-30	Dkr55.03	Dkr0.08	x
2010-09-30	Dkr60.03	Dkr0.08	x
2011-09-30	Dkr46.29	Dkr0.08	x
2012-09-30	Dkr20.64	Dkr0.08	x
2013-09-30	Dkr-69.55	Dkr0.08	x
2014-09-30	Dkr49.41	Dkr0.08	x
2015-09-30	Dkr4.37	Dkr0.08	x
2016-09-30	Dkr4.98	Dkr0.08	x
2017-09-30	Dkr3.83	Dkr0.08	x
2018-09-30	Dkr3.26	Dkr0.08	x
2019-09-30	Dkr0.33	Dkr0.08	x
2020-09-30	Dkr1.08	Dkr0.08	x
2021-09-30	Dkr0.77	Dkr0.08	x
2022-09-30	Dkr1.04	Dkr0.08	x
2023-09-30	Dkr0.02	Dkr0.08	x
2024-09-30	Dkr0.05	Dkr0.08	x
2025-09-30	Dkr0.02	Dkr0.08	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pharma Equity Group A/S Cl A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -99.65%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.53x
Recent ROE (-99.65%) is below the historical average (-38.73%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2008	-164.74%	0.00%	0.00x	4.65x	Dkr-98.29 Million
2009	-25.74%	0.00%	0.00x	1.62x	Dkr-16.71 Million
2010	-2.67%	-273.69%	0.00x	9.37x	Dkr-6.72 Million
2011	-21.31%	-109.63%	0.03x	6.37x	Dkr-24.94 Million
2012	-118.94%	-326.58%	0.03x	13.85x	Dkr-46.92 Million
2013	0.00%	-287.29%	0.20x	0.00x	Dkr-131.28 Million
2014	-6.07%	-4492.42%	0.00x	1.27x	Dkr-15.70 Million
2015	-2.92%	-447.26%	0.00x	1.33x	Dkr-12.26 Million
2016	-1.11%	-98.20%	0.01x	1.35x	Dkr-10.35 Million
2017	0.21%	0.00%	0.00x	1.01x	Dkr-8.33 Million
2018	-9.94%	0.00%	0.00x	1.04x	Dkr-15.47 Million
2019	-21.47%	0.00%	0.00x	1.20x	Dkr-21.13 Million
2020	-95.90%	0.00%	0.00x	1.68x	Dkr-36.30 Million
2021	12.67%	0.00%	0.00x	1.50x	Dkr1.14 Million
2022	7.56%	0.00%	0.00x	1.54x	Dkr-1.13 Million
2023	-97.14%	0.00%	0.00x	2.67x	Dkr-27.14 Million
2024	-49.97%	0.00%	0.00x	1.34x	Dkr-29.31 Million
2025	-99.65%	0.00%	0.00x	1.53x	Dkr-27.93 Million

Industry Comparison

This section compares Pharma Equity Group A/S Cl A's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $8,975,161,000
Average return on equity (ROE) among peers: 2.89%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Pharma Equity Group A/S Cl A (PEG)	Dkr25.47 Million	-164.74%	0.53x	$15.17 Million
ALK-Abelló A/S (ALK-B)	$3.29 Billion	-4.80%	0.51x	$8.27 Billion
Bavarian Nordic (BAVA)	$1.21 Billion	-26.86%	0.64x	$2.36 Billion
Genmab A/S (GMAB)	$31.61 Billion	13.77%	0.12x	$16.60 Billion
Gubra A/S (GUBRA)	$151.46 Million	44.85%	0.99x	$878.04 Million
Zealand Pharma A/S (ZEAL)	$8.62 Billion	-12.52%	0.10x	$3.47 Billion

About Pharma Equity Group A/S Cl A

CO:PEG Denmark Biotechnology

Market Cap

$15.17 Million

Dkr96.98 Million DKK

Market Cap Rank

#25958 Global

#118 in Denmark

Share Price

Dkr0.08

Change (1 day)

+1.80%

52-Week Range

Dkr0.07 - Dkr0.15

All Time High

Dkr2.81